IFNA1 and Middle East respiratory syndrome: As mentioned above, animal model studies on COVID19-related MERS (Middle East Respiratory Syndrome) and SARS diseases have shown that IFN-α/β therapy might be beneficial in the early inflammatory phase of both diseases, whereas the same therapy can be harmful in the late phase of the diseases [50,51] (Figure 2).